Answers are grounded in this paper and cite their sources.
This study examines whether R&D intensity moderates the relationship between intellectual capital efficiency and operating performance among publicly listed pharmaceutical firms in six ASEAN countries. The sample comprises 596 firm-year observations from 70 firms over the 2015–2024 period and is analysed using a two-way fixed-effects model. Intellectual capital efficiency is measured using the Value-Added Intellectual Coefficient (VAIC), operating performance by return on invested capital (ROIC) and R&D intensity by R&D expenditure relative to sales. The baseline results show a positive but statistically insignificant association between VAIC and ROIC. Contrary to the hypothesised positive moderation, the contemporaneous VAIC–R&D interaction is negative and statistically significant in the combined sample. The marginal effects remain positive at the three evaluated R&D levels, namely 0%, the sample mean and the 90th percentile, suggesting attenuation rather than reversal at these levels. Component-level analysis reveals heterogeneous patterns, with positive interactions for HCE and CEE but a negative interaction for SCE. Although the negative interaction is retained under several alternative specifications, the lagged interaction is not statistically significant, and excluding Singapore reverses the contemporaneous interaction to a positive coefficient. The contribution centres on a weakening contemporaneous VAIC–ROIC association whose generalisability is limited by sensitivity to predictor timing and country composition. Unresolved endogeneity further precludes interpreting this association as a causal mechanism.
No takes yet. Share an insight, caveat, or question.
Andriati et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: